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Abstract: The radial spatial positioning of individual gene loci within interphase nuclei has been
associated with up- and downregulation of their expression. In cancer, the genome organization may
become disturbed due to chromosomal abnormalities, such as translocations or deletions, resulting in
the repositioning of genes and alteration of gene expression with oncogenic consequences. In this
study, we analyzed the nuclear repositioning of HLXB9 (also called MNX1), mapping at 7q36.3,
in patients with hematological disorders carrying interstitial deletions of 7q of various extents,
with a distal breakpoint in 7q36. We observed that HLXB9 remains at the nuclear periphery, or is
repositioned towards the nuclear interior, depending upon the compositional properties of the
chromosomal regions involved in the rearrangement. For instance, a proximal breakpoint leading
the guanine-cytosine (GC)-poor band 7q21 near 7q36 would bring HLXB9 to the nuclear periphery,
whereas breakpoints that join the GC-rich band 7q22 to 7q36 would bring HLXB9 to the nuclear
interior. This nuclear repositioning is associated with transcriptional changes, with HLXB9 in the
nuclear interior becoming upregulated. Here we report an in cis rearrangement, involving one single
chromosome altering gene behavior. Furthermore, we propose a mechanistic model for chromatin
reorganization that affects gene expression via the influences of new chromatin neighborhoods.
Keywords: genome organization; radial positioning; chromosome deletion; HLXB9 gene; MNX1
gene; chromosome 7; leukemia
1. Introduction
The behavior of the genome within interphase nuclei gives us essential insights into the spatial
and epigenetic regulation of gene expression [1,2]. The spatial positioning of different genomic regions
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within nuclei is non-random, and depends on the genome composition, in particular gene density
and guanine-cytosine (GC)-content. The GC-richest regions, usually abundant in genes and more
transcriptionally active, are positioned towards the nuclear interior, whereas the GC-poorest regions,
characterized by a paucity of genes, are located towards the nuclear periphery, and are associated with
gene silencing [3–9]. The spatial positioning of the GC-rich and GC-poor regions gives rise to a zig-zag
arrangement of chromatin with a differential spatial location of individual bands that are adjacent to
an individual chromosome, as demonstrated for human chromosome 7 in the cell nuclei of normal
lymphocytes [5,10–17].
This nuclear distribution is further supported by evidence gathered using chromosome
conformation-capture techniques such as the Hi-C method, that provide a high-resolution view
of the genome in its three-dimensional (3D) organization and the interactions of higher-order
chromatin structures within it [18]. These studies showed the presence of two genomic nuclear
compartments, called A and B, localized at the nuclear interior (A) and at the periphery (B), that
correspond to transcriptionally-active GC-rich/gene rich and transcriptionally-inactive GC-poor/gene
poor compartments respectively [19–21]. The Hi-C methods also allowed the identification of distinct
structural units called Topologically Associating Domains (TADs) with size ranging from a few kb to
several Mb, defined by a higher frequency of chromatin interactions within these confined regions,
with little or no interactions beyond their boundaries [22,23]. Previous studies suggested that gene
silencing at the nuclear periphery is a consequence of interactions with the nuclear lamina [24,25].
In fact, certain transcriptionally-silent TADs are further organized into Lamina Associated Domains
(LADs), which are genomic regions in contact with the nuclear lamina at the nuclear periphery, and are
characterized by repressed or minimal transcriptional activity [26].
Although gene density/GC content seem to be the underlying factors crucial forgenome
organization, in proliferating cells individual chromosomes and genes can be non-randomly relocated
to other nuclear compartments during development and differentiation to accomplish specific
transcriptional needs [14,27,28]. In cancer, alterations to specific chromosomes and gene locations
in nuclei are particularly noticeable [29–32]. These findings imply that genomic rearrangements
occurring in cis could also affect the 3D genome organization due to different chromosomal regions
being erroneously positioned in various nuclear compartments [33–37].
Our earlier studies have described the localization of HLXB9 (also known as MNX1), a homeobox
gene mapping at 7q36.3, at the nuclear periphery in phytohaemagglutinin (PHA)-stimulated
lymphocytes from healthy subjects [10], as well as its repositioning in the nucleus of leukemic
cells as a consequence of a chromosomal translocation [38]. In this case, the HLXB9 allele translocated
to the chromosomal band 12p13, a region that is usually found in the inner part of the nucleus, moves
toward the nuclear interior. We speculated that this repositioning of HLXB9 is associated with its
activation in leukemias with t(7;12)(q36;p13) [38,39].
HLXB9 encodes the transcription factor HB9, involved in embryonic development for pancreatic
and neuronal tissue differentiation [40,41]. While mutations of HLXB9 are well known to be associated
with the developmental disorder Currarino syndrome [42], its role in cancer is still unresolved.
A number of reports have described HLXB9 overexpression in malignancies other than leukemia,
including breast cancer [43,44], prostate cancer [45], bladder cancer [46], colorectal cancer [47], liver
cancer [48], neuroblastoma [28], and pancreatic tumors [49], making HLXB9 an interesting gene in
cancer biology. Owing to its function as a transcription factor, the tumorigenic activity of HLXB9
could be attributable to the activation of erroneous transcription programs, via molecular mechanisms
and subsets of target genes yet to be identified. Although the HLXB9 gene was first discovered in
B-lymphocytes, there was a lack of consensus about whether HLXB9 is expressed in bone marrow or
peripheral blood cells [50]. Still today, the expression of HLXB9 in normal hematopoietic stem cells is
debated [39,51–54].
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In terms of function, HLXB9 has been suggested to be involved in maintaining stem cell niche by
regulating cell adhesion or cell-to-cell interaction genes [53], and its overexpression has been linked to
induction of senescence and block in differentiation [54].
Abnormalities of chromosome 7 are frequently encountered in hematological disorders, particularly
of the myeloid lineage. Deletions of the long arm of chromosome 7, del(7q), are commonly found
in the myelodysplastic syndrome (MDS), regarded as a form of pre-leukemia, and acute myeloid
leukemia (AML) [55]. These deletions vary in extent from patient to patient, and can encompass
several chromosomal bands [56–59]. Monosomy 7 and del(7q) are also found in Fanconi anemia (FA)
patients who progress to develop MDS or AML [60]. Moreover, the majority of deletions are interstitial,
meaning that the 7q telomere and subtelomeric region, including the HLXB9 gene, are retained.
Understanding the chromosome 7 biology in leukemia is of interest both from a clinical and
mechanistic perspective. A number of candidate genes possibly involved in leukemogenesis are
found in the 7q region [55], with HLXB9 arousing particular interest. These observations prompted
us to investigate the radial nuclear positioning of HLXB9 in the nuclei of cells from hematological
patients harboring deletions of different sizes and breakpoints along the long arm of chromosome 7.
In this study, we investigated the behavior of the HLXB9 gene in hematological disorders, including
expression patterns in a large patient cohort. In particular, we aim to address a number of key questions
surrounding the altered nuclear positioning of HLXB9 in leukemia with deletions of chromosome 7,
and to identify any associations between the observed location, and changes in gene expression, size of
the deletion, and cytogenetic mapping of affected chromosomal bands.
2. Results
2.1. Data Mining of HLXB9 Expression
We investigated the expression of HLXB9 in acute myeloid leukemia (AML) and Acute
lymphoblastic leukemia (ALL) by taking advantage of the available data from The Cancer Genome
Atlas (TCGA), and the Therapeutically Applicable Research to Generate Effective Treatments (TARGET)
initiative. We extracted and analyzed 369 AML and 544 ALL samples, of which 173 AML samples form
TCGA had associated information regarding their cytogenetics. Data from 337 whole blood samples
and 140 replicates of the K562 leukemia cell line from the Genotype-Tissue Expression (GTEx) project
were used as negative and positive controls, respectively, for HLXB9 expression. Overall, similar levels
of HLXB9 expression are observed in the majority of samples in ALL, AML and whole blood, when
compared to the K562 cell line, which shows significantly higher expression (Figure 1, Supplementary
Materials Figures S1,S2). However, a number of samples within the ALL and AML cohorts were
distinguishable by a higher expression of HLXB9 compared to whole blood. We explored whether this
may be associated with the cytogenetic features in the AML samples (cytogenetic data was unavailable
for ALL). Using a cut-off value of 1 for the log2 normalized expression level, we were able to identify 7
samples characterized by the presence of del(7q) with high HLXB9 expression. Detailed phenotypic
information of these cases is reported in Table S1. We subdivided the entire AML cohort in 4 classes
based on the presence of a del(7q), according to the reported cytogenetic abnormality (Figure 2).
Overall, about 30% of samples with a del(7q), alone or in conjunction with other abnormalities, shows
expression of HLXB9. A detailed overview of HLXB9 expression levels across all cytogenetic groups is
shown in Supplementary Materials Figure S3.
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Figure 1. HLXB9 expression-level distribution in acute myeloid leukemia (AML), acute lymphoblastic 
leukemia (ALL), whole blood and K562 leukemia cell line. The number of samples in each dataset is 
given above. Whole blood and K562 samples were extracted from Genotype-Tissue Expression 
(GTEx). AML is a composite dataset combining cross-project normalized samples from The Cancer 
Genome Atlas (TCGA)(173 samples) and the Therapeutically Applicable Research to Generate 
Effective Treatments (TARGET) (196 samples). **** p<0.0001. 
 
Figure 2. HLXB9 expression level distribution in 173 TCGA AML samples stratified by cytogenetic 
phenotypes, where "n" signifies the total number of samples in each class, while "expressed" indicates 
the number of samples with HLXB9 expression level higher than 1. 
2.2. Classification of Large Series of Patients Based on HLXB9Expression Patterns 
Altogether, we collected a total of 58 samples from patients with various hematological 
disorders, including myelodysplastic syndrome (MDS) and myeloproliferative disorder (MPD) (n = 
11), acute lymphoblastic leukemia (ALL) (n = 6), acute myeloid leukemia (AML) (n = 27), chronic 
myeloid leukemia (CML) (n = 2), and Fanconi anemia (FA) (n = 2) (Figure 3A). Expression of HLXB9, 
assessed by reverse transcription polymerase chain reaction (RT-PCR), was detected in 15 samples 
out of 58. For 6 samples the expression of HLXB9 is unknown, due to lack of sufficient material. 
According to the karyotypes available, we subdivided the entire cohort into patients with 
chromosome 7 abnormalities (n = 45), and patients without chromosome 7 abnormalities (n = 8); for 
5 patients the karyotype was unavailable. 10 patients with chromosome 7 abnormalities expressed 
Figure 1. HLXB9 expression-level distribution in acute myeloid leukemia (AML), acute lymphoblastic
leukemia (ALL), whole blood and K562 leukemia cell line. The number of samples in each dataset
is given above. Whole blood and K562 samples were extracted from Genotype-Tissue Expression
(GTEx). AML is a composite dataset combining cross-project normalized samples from The Cancer
Genome Atlas (TCGA)(173 samples) and the Therapeutically Applicable Research to Generate Effective
Treatments (TARGET) (196 samples). **** p < 0.0001.
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Figure 2. HLXB9 expression level distribution in 173 TCGA AML samples stratified by cytogenetic
phenotypes, where “n” signifies the total number of samples in each class, while “expressed” indicates
the number of samples with HLXB9 expressio level higher than 1.
2.2. Classification of Large Series of Patients Based on HLXB9Expression Patterns
Altogether, we collected a total of 58 samples from patients with various hematological disorders,
including my lodysplastic syndrom (MDS) and myeloprolif r tive disorder (MPD) (n = 11), acute
lymphoblastic leuke ia (ALL) (n = 6), acute myeloid leukemia (AML) (n = 27), chronic myeloid
leukemia (CML) (n = 2), and Fanconi anemia (FA) (n = 2) (Figure 3A). Expression of HLXB9, assessed
by revers transcription polymer se chain reaction (RT-PCR), was detected in 15 samples out of 58.
For 6 samples th expression of HLXB9 is unknown, du to lack of sufficient mat rial. According to the
kary types available, w subdivided the entire cohort into patie ts with chrom some 7 abnormalities
(n = 45), and patients without chromosome 7 abnormaliti s (n = 8); for 5 patients the karyotype as
unavailable. 10 patients with chromosome 7 abnormalities expressed HLXB9(29 did not express HLXB9,
6 N/A); 3 patients without chromosome 7 abnormalities out of 8 were positive (Figure 3B).
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Figure 3. HLXB9 expres ion pat erns in the pati l . (A) Graph showing proportion of
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and patients with an unknown karyotype. (C) HLXB9 expressio in patients with chrom some 7q
abnormalities by subtype (interstitial, terminal, i t rstiti l t r inal, and other).
We further subdivided the chromosome 7 abnormality cohort by type—patie ts with int stitial
deletions (n = 14), terminal deletions (n = 14), interstitial and terminal deletions (n = 5), and other
(e.g., insertions, additions, ring, etc.) (n = 12). When these groups were investigated for the expression
of HLXB9, 5 patients had an interstitial deletion of 7q; 1 had a terminal deletion, and 4 had other types
of chromosome abnormality (Figure 3C). By classifying the patients based on their diagnosis, we found
that HLXB9 was expressed in 3 patients diagnosed with MDS or MPD, 2 with ALL, 5 with AML, and 1
with FA. Out of 10 patients with an unknown diagnosis, 4 cases showed HLXB9 expression (Figure 3A).
2.3. Deletion Mapping of Breakpoints, Radial Nuclear Location and Expression Analyzes in a Selected Series
of Patients
From the series of 58 patient samples, we selected 0 (referred to as Pt-1 to Pt-10) with interstitial
deletions of the long arm of chromosome 7, for which we had good quality material to enable us
to conduct further molecular cytogenetic characterization and expression analysis. The clinical and
cytogenetic details are reported in Table 1.
Table 1. Clinical and cytogenetic features of the patients analyzed in this study.
Pt Diagnosis Karyotype Reference
1 CMML 46,del(7)(q21q36) [61]
2 MDS 46,XY,del(7)(q21.3-22q36) [58,61]
3 AML-M5 46,XX,del(7)(q22q36) [58]
4 MDS 46,XY,del(7)(q22q36) [61]
5 MDS 45,XX,del(5)(q14),del(7)(q22), del(9)(q22),-17 This study
6 CML 47,XY,del(7)(q21),+21[20] 1 This study
7 FA 46,XY,dup(1)(q24q44),del(7)(q21)[5] 1 This study
8 AML-M6 44,XY, (1;3)(p21;?),-5,del(7)(q31.1),-17,-20,+mar[cp18] 1 This study
9 t-AML 46,XX,del(7)(q32.1[4]/46,XX[6] This study
10 AML 47,XY,+8[11]/47,idem,del(7)(q32.1)[9] This study
Notes: Pt: Patient; CMML: Chronic myelomonocytic leukemia, MDS: Myelodysplastic syndrome; AML-M5: Acute
myeloid leukemia M5 subtype, CML: Chronic myeloid leukemia, FA: Fanconi anemia, AML-M6: Acute myeloid
leukemia M6 subtype, while also t-AML represents therapy-related acute myeloid leukemia.Archival samples
from these patients were originally contributed by the Oncogenetic Laboratory, Children’s Hospital, University of
Giessen, Germany (Pt. 1 to 4) and by the Pediatric Hematology Department, San Gerardo Hospital, Monza, Italy
(Pt-5). 1 Original karyotypes were refined byfluorescence in situ hybridization (FISH) (see Table 2).
2.3.1. Characterization of del(7q) Breakpoints
Characterization of deletion breakpoints relied on both conventional karyotype analysis at the time
of diagnosis (Table 1), and FISH (Table 2). We previously used FISH to map precisely the breakpoints
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in Pt-1 to Pt-4 in our earlier studies [58,61]. Here, for Pt-5 to Pt-10, we used FISH with probes localized
along the long arm of chromosome 7 to determine the proximal and distal breakpoints of the del(7q),
and whether the HLXB9 locus is retained in the deleted chromosome, to refine the karyotypes in
some cases. For Pt-4 and Pt-5, the samples were of insufficient amount to allow further experiments
needed to establish more precise breakpoints. Representative FISH images are shown in Figure 4.
The presence of two hybridization signals for the locus-specific probe for HLXB9 (RP5-1121A15) at
7q36.3 in all 10 patients confirmed that HLXB9 was retained in all cases. In Pt-1 to Pt-5, this is shown
in metaphases by the presence of a deleted chromosome 7 shorter than the normal homolog painted
in green, and both HLXB9 loci detected in red by RP5-1121A15. In Pt-6 to Pt-10, two HLXB9 alleles
are shown in metaphases, and nuclei hybridized by the same probe. Hybridization with the probe
mixture containing the EZH2 locus at 7q36.1 further narrowed down the distal breakpoint in Pt-7
and Pt-8, which was mapped at 7q36.2, due to the absence of signals for this probe on the deleted
chromosome. Pt-6, Pt-9 and Pt-10 had both signals for EZH2, indicating that the distal breakpoint lies
on a region proximal to it, but could not be further determined. In Pt-6 to Pt-10, the 7q21.11 region was
retained, as shown by two signals for the RP11-90N9 probe. Pt-6 and Pt-7 showed loss of the 7q22 and
7q31 regions on the deleted chromosomes, as shown by single signals for probes containing KMT2E
(7q22), RP11-213E22 (7q22.1) and MET (7q31.2), indicating that the breakpoint lies in 7q21. These loci,
however, were retained in Pt-9 and Pt-10. The breakpoint in Pt-8 was mapped at 7q22, considering
that the 7q34, and 7q31.2signals were lost. In Pt-9 and Pt-10, signals for the 7q31 region were present,
placing the proximal breakpoint further away, compared to other patients, approximately between
7q32 or 7q33. Given that only one signal for RP11-73H23 at 7q34 is seen in Pt-6 to Pt-10, and that
the HLXB9 locus at 7q36.3 is consistently kept, we concluded that the deletions were all interstitial,
with the distal breakpoint in 7q35/q36, and a variable proximal breakpoint between 7q21 and 7q33.
Together with our previous analysis of Pt-1 to Pt-4 [58,61], we can summarize the proximal breakpoints
as follows: In the 7q21 band in Pt-1, Pt-2, Pt-6 and Pt-7; in the 7q22 band in Pt-3, Pt-4, Pt-5 and Pt-8;
in the 7q32/33 region in Pt-9 and Pt -10. A graphical view of the breakpoints in each patient, and the
GC-content along chromosome 7 is shown in Figure 5.
Table 2. Fluorescence in situ hybridization (FISH) mapping of chromosome 7 deletion breakpoints.
Probes Band
Patients
Pt.1 Pt.2 Pt.3 Pt.4 Pt.5 Pt.6 Pt.7 Pt.8 Pt.9 Pt.10
RP11-90N9 7q21.11 + + + + +
Cos 5.2 7q21.3 +
RP11-213E22 7q22.1 − − + + +
Cos 7d.2 7q22.1 −
Cos 8a.2 7q22.1 −
Cos 1120 7q22.1 −
PAC 1065 (CUTL1) 7q22.1 +
KMT2E gene 1 7q22 − − + + +
HSC7E485 7q22.2 − −
MET gene 1 7q31.2 − − − + +
RP11-73H23 7q34 − − − − −
HSC7E124 7q36.1 − −
EZH2 gene 1 7q36.1 + − − + +
HSC7E86 7q36.2 − +
HSC7E769 7q36.2 +
RP5-1121A15 7q36.3 + + + + + + + + + +
Notes: The probes listed in this table have been described before [10,58]. + and − indicate retention or loss of the
relative genomic region on the deleted chromosome 7. 1 probes from MetaSystems; empty spaces in correspondence
to a probe, indicate no data available regarding retention or loss of the locus.
Cancers 2019, 11, 585 7 of 19
Cancers 2019, 11, x 7 of 19 
 
 
Figure 4. Fluorescence in situ hybridization (FISH) patterns observed in metaphases and nuclei of 
patients with del(7q). The 7q deletion breakpoints in Pt-1 to Pt-10 were determined by dual-color FISH 
using different probes, indicated at the bottom of each panel. The HLXB9 gene was detected using the 
BAC probe RP5-1121A15 (7q36.3). KMT2E (7q22) + MET (7q31.2) and KMT2E + EZH2 (7q36.1) were 
detected using commercial probe mixtures from MetaSystems. Whole chromosome paint 7, RP11-
90N9 (7q21.11), RP11-211E22 (7q22.1), and RP11-73H23 (7q34) are BAC probes previously described 
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Figure 4. Fluorescence in situ hybridizati ( I ) tt r s observed in metapha es and nuclei of
patients with del(7q). The 7q deletion breakpoi ts i t-1 to Pt-10 were determined by dual-color FISH
using different probes, indicated at the bottom of each panel. The HLXB9 gene was detected using the
BAC probe RP5-1121A15 (7q36.3). KMT2E (7q22) + ET (7q31.2) and KMT2E + EZH2 (7q36.1) were
detected using commercial probe mixtures from MetaSystems. Whole chromosome paint 7, RP11-90N9
(7q21.11), RP11-211E22 (7q22.1), and RP11-73H23 (7q34) are BAC probes previously described
(see Materials and methods). Metaphase chromosomes and interphase nuclei were counter-stained in
blue with DAPI. Magnification 1000×.
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2.3.2. HLXB9 Radial Nuclear Location
We determined the radial nuclear location (RNL; expressed as median values) of the 7q36 region
encompassed by RP11-1121A15 (containing the HLXB9 gene) in the 10 selected patient samples
(Figure 6). Observations were carried out on both homologs, normal chromosome 7 and deleted
chromosome whenever possible, depending on sample quality. Data for Pt-1 to Pt-5 were obtained
using single-color FISH with the probe RP11-1121A15. This approach did not enable us to discriminate
between the normal chromosome 7 and the deleted one. As a consequence, data are skewed by the
presence of the HLXB9 allele on the non-deleted chromosome. The use of dual-color FISH in the
other cases (Pt-6 to Pt-10) enabled us to discriminate between the two chromosomes, hence to obtain
the individual RNL of the two HLXB9 alleles (“7nor” and “7del” in Figure 6). For Pt-8, although a
dual-color approach was used, the RNL was calculated based on both alleles, since it was not possible
to clearly identify the allele on the deleted chromosome from the non-deleted one. Overall, our
analysis revealed that for Pt-1, Pt-2, Pt-6, Pt-7, Pt-9 and Pt-10, HLXB9 is located in the peripheral
region of the nucleus (i.e. RNL higher than 0.650), which is the same compartment where the gene is
located in the controls phytohaemagglutinin (PHA)-stimulated lymphocytes (left panel in Figure 6).
By contrast, Pt-3, Pt-4, Pt-5 and Pt-8 showed that HLXB9 was positioned more internally in the nucleus
(i.e. RNL lower than 0.650), compared to the controls (statistical differences highly significant, p <
0.0001 for Pt-3, Pt-5 and Pt-8 and p < 0.001 for Pt-4) (Figure 6). In the cases where we were able to
distinguish between the normal and deleted chromosomes (i.e. Pt-6, Pt-7, Pt-9 and Pt-10), HLXB9 in the
deleted chromosome 7 of Pt-7 (RNL = 0.754) and Pt-9 (RNL = 0.722), is located even more peripherally
compared to the controls, and compared to the allele belonging to the non-deleted chromosome (p <
0.0001 and p < 0.001, respectively). HLXB9 in Pt-6 maintains a nuclear location similar to that of the
control, and there is no significant difference between the normal and deleted chromosomes. In Pt-10
the allele located in the normal chromosome 7 is more internal than the control (p < 0.05).
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Figure 6. Radial nuclear location (RNL) of t s i el(7q) patients. The graph displays
median value and relative confidence inter l onding to the RNL of the HLXB9 locus in
patients and controls. On the left are t f t o ic loci 90N9 (7q2 .11), 213E22 (7q22.1),
KMT2E (7q22.3), MET (7q31.2), 73H23 (7q34) a 9 in nuclei of control cells (lymphocytes from
peripheral blood of volunteer healthy donors fro [10]). n the right side, each RNL value refers to
the HLXB9 gene in the indicated patients (Pt-1 to Pt-10). For Pt-6, Pt-7, Pt-9, and Pt-10 the two alleles
were measured separately: 7nor and 7del indicate HLXB9 in the normal or deleted chromosome 7,
respectively. In the other cases, the RNL value refers to both HLXB9 alleles, as it was not possible to
discriminate between the two, due to a low number of informative nuclei. The dashed line at 0.65
indicates the median value separating the peripheral and the internal nuclear compartment, i.e. values
higher than 0.65 are peripheral, and values lower than 0.65 are internal to the nucleus. Statistical
significance of the difference in the RNL data obtained for each probe with respect to the HLXB9 in
the control cells (name underlined, and RNL indicated by an enlarged spot), was evaluated using the
two-tailed t tests. p values are: * p < 0.05, ** p < 0.001, *** p < 0.0001.
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2.3.3. HLXB9Expression
HLXB9 expression analysis revealed the presence of the HLXB9 transcript in Pt-4, Pt-8, and
Pt-10, but not in Pt-2, Pt-6, Pt-7, and Pt-9 (Figure 7). Insufficient material from Pt-1, Pt-3 and Pt-5
did not enable us to carry out the analysis in these samples. The amplified transcript corresponds
to the predicted fragment of 359 bp, demonstrating the presence of the HLXB9 transcript in these
samples. By comparing HLXB9 expression with its radial nuclear location and the GC-content of
the chromosomal region in the vicinity of the proximal brakpoint, we observed a high degree of
concordance of these three parameters: (1) HLXB9 is expressed, (2) HLXB9 is localized in the nuclear
interior, and (3) high GC-level of the involved chromosomal region; or, in the opposite case, (1) HLXB9
is not expressed, (2) HLXB9 localizes at the nuclear periphery, and (3) low GC-level of the involved
chromosomal region (Table 3).
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Figure 7. Detection of the HLXB9 transcript in patient samples with del(7q). Agarose gel electrophoresis
containing nested reverse transcription (RT)-PCR products obtained using primers specific for HLXB9.
The molecular marker (M) is peqGOLD DNA-Sizer XI (range 67-1118 bp, PeqLab, Fareham, UK). The
amplified DNA fragment, indicated by black arrows, corresponds to theexpected size of the HLXB9
transcript (359 bp). The transcript is clearly present in Pt-4, Pt-8 and Pt-10. Positive controls are the
leukemia-derived cell line K562 and another patient sample (Cnt+), known to express HLXB9 (patient
no. 10 in [38]).
Table 3. HLXB9 gene positioning and expression in the patients analyzed in this study.
HLXB9Expression RNL GC-level (a) Pt ID
Not Expressed 0.754(•) GC-poor 7
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3. Discussion
Increased expression of the homeobox gene HLXB9 has been described in several cancers, including
leukemia [28,38,39,43–49,52]. However, little is known about the oncogenic mechanisms of HLXB9.
In a specific type of infant leukemia, HLXB9 transcription seems to be triggered by the chromosomal
rearrangement t(7;12)(q36;p13), where the breakpoint on chromosome 7 lies proximal to HLXB9 [64].
It has been proposed that HLXB9 may act as a tumor suppressor in AML, and oncogene in ALL [65].
Our interests focus on understanding gene repositioning in the context of nuclear architecture and
genome organization as possible mechanisms of HLXB9 activation in hematological malignancies.
In this study, we aimed to address (i) whether there are consistent patterns of HLXB9 expression in
a broad variety of hematological disorders, (ii) if HLXB9 expression is associated with the presence
of chromosome 7 abnormalities, (iii) if HLXB9 expression in del(7q) patients varies depending on
chromosomal breakpoints, (iv) if HLXB9 expression status is associated with the positioning of the
gene in particular nuclear compartments.
3.1. HLXB9 Expression is Not Associated with Any Specific Leukemia Subtype
In this study, we looked at HLXB9 expression in publicly-available databases (TCGA, TARGET
and GTEx; Figures 1 and 2), and in a cohort of 58 patients with various hematological disorders by
RT-PCR (summarized in Figure 3). Across the datasets, HLXB9 expression in the majority of samples
was comparable to that of normal blood. However, it was evident that a number of outliers are spread
at higher expression levels in AML and ALL, suggesting that HLXB9 expression could be linked to
features other than diagnosis. Similarly, data gathered from our 58 patient samples showed HLXB9
expression in approximately 20% of cases. From our initial survey of the total patient cohort according
to diagnosis (Figure 3A), the patterns of HLXB9 expression varied, and was not particularly prominent
in any diagnostic group. A higher number of positive patients was noticed in the MDS-MPD and AML
groups, consistent with the higher incidence of chromosome 7 abnormalities in these disorders. The
small sample sizes for the two patients with FA limited our interpretation for HLXB9 expression in this
subgroup. These observations are in line with the description of HLXB9 overexpression in a variety of
malignancies unrelated to the hematopoietic system, some of which correlate with the role of HLXB9
in pancreatic and neuronal development in the embryo [28,43–49].
3.2. HLXB9 Expression is Not Necessarily Associated with the Presence of Chromosome 7 Abnormalities
The expression of HLXB9 according to cytogenetic subgroups in public databases correlated with
our observations in the patient cohort (Figures 2 and 3). Approximately 30% of patients with del(7q),
alone or in conjunction with other rearrangements, showed expression of HLXB9, when compared
to 20–25% of normal karyotypes or other subgroups. The expression of HLXB9 in patients without
chromosome 7 abnormalities indicates that its activation may not be solely dependent on chromosome
7 rearrangements. It should be taken into consideration that a proportion of patients presents cryptic
abnormalities or microdeletions of 7q [39,66], which may go unnoticed by conventional karyotyping,
and become misclassified in the studied cohorts. Similarly, it cannot be excluded that rearrangements
of other chromosomes may bring about changes in nuclear organization that indirectly activate other
genes in trans. However, among patients with chromosome 7 abnormalities in our cohort, HLXB9
was expressed at a higher proportion in patients with interstitial deletions of 7q, and those with other
chromosome 7 abnormalities (e.g. rings, additions, translocations), when compared to patients with
terminal deletions (i.e. with loss of the HLXB9 allele on the deleted chromosome). It was not possible
to compare this data with published datasets due to the lack of cytogenetic information in the latter.
3.3. HLXB9 is Expressed When del(7q) Proximal Breakpoint Lies in a GC-rich Genomic Region
The 10 samples used in the present work were characterized by an interstitial deletion of the
long arm in one of the two chromosomes 7. The deletions spanned from few to several chromosomal
bands, and the deleted segment did not include the HLXB9 gene, located at 7q36.3, at about 2.3 Mb
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from the telomere (Figure 5). Each deletion determined a specific repositioning of HLXB9 in the
nucleus, depending on the GC-content of the chromosomal region close to the proximal breakpoint.
We compared the HLXB9expression status of each patient with the RNL of HLXB9 and the compositional
properties of the chromosomal region close to the centromeric breakpoint, observing a large degree of
concordance with these three parameters (Table 3). We observed that deletions causing a repositioning
of the 7q36 region near the GC-poor bands 7q21 (Pt-1, Pt-2, Pt-6 and Pt-7) or 7q31 (Pt-9 and Pt-10),
result in a more peripheralnuclear localization of the HLXB9 allele. Conversely, deletions joining the
telomeric end of chromosome 7 with the GC-rich 7q22 band (Pt-3, Pt-4, Pt-5 and Pt-8) result in an inner
nuclear localization of HLXB9.
Thus, the transcriptional activation of HLXB9 occurs only in those cases carrying a deletion of
chromosome 7 where the gene moves to the more internal part of the nucleus. Indeed, two cases
(Pt-4 and Pt-8) showed a relocation of HLXB9 in the inner part of the nucleus and activation of its
transcription. Incidentally, in Pt-10, HLXB9 expression was also observed, but the allele re-located
to the inner part of the nucleus belongs to the non-deleted chromosome 7. In this latter case, we can
hypothesize that transcriptional activation could be due to anectopic activation of this allele, and may
indicate a more complex mechanism leading to gene activation in leukemia. We described a similar
scenario in the leukemia cell line GDM-1 where, in the presence of the translocation t(6;7)(q23;q36),
the activation of HLXB9 seems to arise from the non-affected chromosome [32]. It is to be noted that
it is still a topic of debate whether HLXB9 is active in non-pathological conditions and in certain
differentiated cells, other than during embryonic development [39,51–54].
3.4. Mechanisms Leading to HLXB9 Re-positioning in the Nucleus
Although the biology of hematological disorders with del(7q) is still largely unknown, the del(7q)
seems to have an important role in tumor emergence and progression [67–69]. We speculate that the
oncogenic mechanisms of del(7q) leukemia rely on differences in gene expression patterns that reflect
different deletion breakpoints (Figure 8). Deletions involving different chromosomal bands might lead
to the activation or silencing of different gene pathways due to alteration of the nuclear architecture
and genome organization.
Cancers 2019, 11, x 11 of 19 
 
from the telomere (Figure 5). Each deletion determined a specific repositioning of HLXB9 in the 
nucleus, depending on the GC-content of the chromosomal region close to the proximal breakpoint. 
We compared the HLXB9expression status of each patient with the RNL of HLXB9 and the 
compositional properties of the chromosomal region close to the centromeric breakpoint, observing 
a large degree of concordance with these three parameters (Table 3). We observed that deletions 
causing a repositioning of the 7q36 region near the GC-poor bands 7q21 (Pt-1, Pt-2, Pt-6 and Pt-7) or 
7q31 (Pt-9 and Pt-10), result in a more peripheralnuclear localization of the HLXB9 allele. Conversely, 
deletions joining the telomeric end of chromosome 7 with the GC-rich 7q22 band (Pt-3, Pt-4, Pt-5 and 
Pt-8) result in an inner nuclear localization of HLXB9. 
Thus, the transcriptional activation of HLXB9 occurs only in those cases carrying a deletion of 
chromosome 7 where the gene moves to the more internal part of the nucleus. Indee , two cases (Pt-
4 and Pt-8) show d  relocation of HLXB9 in the n er part of the nucleus and activation of its 
transcription. Incidentally, in Pt-10, HLXB9 xpression was als  observed, but the allele e-located to 
the inner par  of the nucleus belongs to the non-deleted chromosome 7. In this latter case, we can 
hypothesize that transcriptional activation could be due to nectopic activation of this allele, and may 
indicate a more co plex mechanism leading to gene activation in leukemia. We described a similar 
scenario in the leukemia cell line GDM-1 where, in the presence of the translocation t(6;7)(q23;q36), 
the activation of HLXB9 seems to arise from the non-affected chromosome [32]. It is to be noted that 
it is still a topic of debate whether HLXB9 is active in non-pathological conditions and in certain 
differentiated cells, other than during embryonic development [39,51–54]. 
3.4. Mechanisms Leading to HLXB9 Re-positioning in the Nucleus 
Although the biology of hematological disorders with del(7q) is still largely unknown, the 
del(7q) seems to have an important role in tumor emergence and progression [67–69]. We speculate 
that the oncogenic mechanisms of del(7q) leukemia rely on differences in gene expression patterns 
that reflect different deletion breakpoints (Figure 8). Deletions involving different chromosomal 
bands might lead to the activation or silencing of different gene pathways due to alteration of the 
nuclear architecture and genome organization. 
 
Figure 8. Distribution of chromosome 7 genomic material across the nucleus. The illustration depicts 
three nuclei with two normal copies of chromosome 7 (left), one chromosome 7 with an interstitial 
deletion involving the region included between 7q21 and 7q36 (middle), and one chromosome 7 with 
an interstitial deletion involving the region included between 7q22 and 7q36 (right). The 
representation of the chromosome 7 territories follows a zig-zag conformation of the DNA, according 
to data previously published [10]. Depending on the extent of the deletion, the terminal region of 7q, 
harboring HLXB9, becomes juxtaposed to either the 7q21 band or the 7q22 bands. The vicinity to the 
7q21 band, positioned at the periphery of the nucleus, determines a peripheral position for HLXB9, 
whereas the vicinity to the 7q22 band, normally positioned towards the inner part of the nucleus, 
causes an alteration in the location of HLXB9, which becomes positioned more internally. Since the 
repositioning potentially alters the gene expression pattern of the affected gene, this could explain the 
ectopic activation of HLXB9 allele repositioned in the inner part of the nucleus. Red and blue 
chromosomal bands correspond to the GC-richest and the GC-poorest bands in the chromosome 7 
[10]. 
Figure 8. Distribution of chromosome 7 genomic at i cleus. The illustration depicts
three nuclei with two normal copies of chromoso ro osome 7 with an interstitial
deletion i vol ing the r gion i clude between 7q21 and 7q36 (mid le), and one chromosome 7 with an
interstitial deletion involving the region included between 7q22 and 7q36 (right). The rep esentation of
the chromosome 7 territories f llows a zig-zag conf rmation of the DNA, according to data previously
published [10]. Depending on the extent of the deletion, the terminal region of 7q, harboring HLXB9,
becomes juxtaposed to either the 7q21 band or the 7q22 bands. The vicinity to the 7q21 band, positioned
at the periphery of the nucleus, determines a peripheral position for HLXB9, whereas the vicinity to
the 7q22 band, normally positioned towards the inner part of the nucleus, causes an alteration in the
location of HLXB9, which becomes positioned more internally. Since the repositioning potentially alters
the gene expression pattern of the affected gene, this could explain the ectopic activation of HLXB9
allele repositioned in the inner part of the nucleus. Red and blue chromosomal bands correspond to the
GC-richest and the GC-poorest bands in the chromosome 7 [10].
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According to our results, the repositioning of HLXB9 in the nucleus of leukemia cells is dependent
on the newly juxtaposed chromosomal region resulting from the deletion. Our observations are
consistent with other reports showing that the repositioning of genes is non-random, and depends on
the properties of neighboring genomic loci [70].
Little is known regarding the mechanisms that induce gene repositioning in the nucleus. Zones of
gene deserts seem to be enriched with lamina-associated domains (LADs) that favor their attachment
to the nuclear lamina, resulting in their transcriptional silencing [26,71]. The distribution of such LADs
along different regions of chromosome 7 (Figure 5) [63] further supports the model ofzig-zag positioning
of chromosome 7 in the nuclei of control lymphocytes (Figure 6) [10]. Theoretically, an interstitial
deletion bringing together two zones of transcriptionally silent LADs at the nuclear periphery would
not produce an effect on the expression of a particular gene. Similarly, a loss of LADs could prevent an
adjacent region from interacting with the nuclear lamina, and becoming transcriptionally active under
a new neighboring structural domain.
3.5. Gene Expression in 3D Chromatin Architecture
Individual gene repositioning within the interphase nucleus should be seen in context with the
more complex 3D organization of the whole genome and chromatin architecture in differentiated or
replicative cells. It was recently shown that evolutionarily successful chromosomal rearrangements do
not alter the nuclear position of the regions involved. This is not the case in pathological situations,
where the rearrangements typically alter the gene structure, and often also the gene nuclear position [32].
Many studies have focused on how gene relocation might affect gene regulation and expression,
in both cell development and disease [14,16,28,38,72,73], and how these alterations are associated
with the interaction with certain structures such as LADs and TADs [24,74,75]. We foresee that
these interactions, higher-order chromatin features, and their disturbance caused by chromosomal
rearrangements, are the key to understanding the oncogenic changes in gene expression, which would
bring us a step closer in comprehending the process of leukemogenesis associated with chromosome
7 aberrations.
Current research on spatial organization of the genome in cancer cells confirms that a
number of genes are consistently repositioned in specific pathologies, such as breast and prostate
cancer [30,31,76–78]. Therefore, the analysis of nuclear gene positioning in cancer could be of diagnostic
value. Some investigations also showed repositioning of whole chromosomes in leukemia samples
prior to relapse, indicating the prognostic value of nuclear positioning studies [79]. Further work is
needed to fully understand the implications of our findings, and if mapping of HLXB9 in the nucleus
of leukemia cells has any diagnostic potential. The prognosis of del(7q) leukemias is known to be
generally very poor, irrespective of breakpoint or extent of deletion. Similarly, the presence of del(7q) in
MDS-MPD and FA patients is a sign of malignant transformation, and hence indicative of poor clinical
outcome. However, the added information coming from HLXB9 repositioning, associated with gene
expression data, might help to refine the classification of these cases, and aid design tailored therapy.
4. Materials and Methods
4.1. Patient Samples
We used archival material from 58 patient samples in the form of fixed chromosome and nuclei
suspensions in methanol:acetic acid, some of which were used in previous studies [38,58,61]. Of these,
we selected 10 samples (Pt-1 to Pt-10, with details in Table 1) with good material quality, enabling
us to carry out more detailed analyzes using fluorescence in situ hybridization (FISH) with several
genomic probes and reverse transcription polymerase chain reaction (RT-PCR), to assess HLXB9
expression. Four patient samples presented in this work (from Pt-1 to Pt-4) were described in earlier
reports [38,58,61]. Archival materials of the six other patients (from Pt-5 to Pt-10) are described here for
the first time. Pt-5 was contributed by Professor Jochen Harbott, Oncogenetic Laboratory, Children’s
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Hospital, University of Giessen, Germany. Pt-6 to Pt-10 were contributed by Associazione Italiana
Ematologia Oncologia Pediatrica (AIEOP), Centro Ricerca Tettamanti, Pediatric Department, University
of Milano-Bicocca, Monza, Italy. A complete karyotype, available in the majority of cases, was obtained
using chromosome banding with standard methods. Moreover, the extent of deletions was refined by
FISH. Ethical approval no: 16516-TISS-Apr/2019-18741-2.
4.2. Control Samples
Control samples from peripheral blood lymphocytes of healthy individuals were prepared and
analyzed previously [10]. Data of radial nuclear location (RNL) published at that time was used as
a reference for the present study. Furthermore, the myeloid leukemia cell line K562, and a patient
positive for HLXB9 expression (patient no. 10 described in previous work [38]), were used as positive
controls for expression analysis based on RT-PCR performed on Pt-6 to Pt-10.
4.3. Reverse Transcription Polymerase Chain Reaction (RT-PCR)
RNA was extracted from archival fixed-chromosome and nuclei suspensions using Qiagen
RNeasy mini Kit (Qiagen, Manchester, UK). cDNA was synthesised using Superscript III reverse
transcriptase kit (Life Technologies, Paisley, UK). Nested RT-PCR was conducted to assess HLXB9
expression using primers and conditions as previously described [38]. Briefly, primers for the first
round of amplification were HB9-WT1f: 5’-CTTCCAGCTGGACCAGTGGCTG-3’ and HB9-WT1r:
5’-CGTCCTCGTCCTCGTCCTCC-3’, and HB9-1994 forward: 5’-TCCACCGCGGGCATGATCCTG-3’
and HB9-WT2 reverse: 5’-GGCCCCAGCAGCTCCTCGGCTC-3’ for the second round.
The amplification conditions were: Denaturation at 94◦C for 3 min, followed by 35 cycles of
annealing at 68 ◦C for 30 s, extension at 68 ◦C for 1 min, final extension at 68 ◦C for 3 min, holding at
4◦C. The predicted size of the amplified DNA segment is 359 bp, based on the available sequence of
the HLXB9 mRNA (accession number: NM_005515.4), also consistent with the results shown by [80].
4.4. Data Mining
Data from the three datasets. The Cancer Genome Atlas (TCGA), Therapeutically Applicable
Research to Generate Effective Treatments (TARGET) and Genotype-Tissue Expression (GTEx), were
obtained from the University of California, Santa Cruz, Xena repository. The raw gene expression
data across the three datasets (TCGA, TARGET, and GTEx) was processed at UCSC using the TOIL
pipeline as described in [81]. All the expression levels for the genes of interest were extracted from
the TCGA-TARGET-GTEX cohort. To investigate the association between expression level and the
cytogenetic phenotype, we extracted phenotypic information from the TCGA acute myeloid leukemia
(AML) and Therapeutically Applicable Research to Generate Effective Treatments (TARGET) acute
lymphoblastic leukemia (ALL)datasets. 7q deletion information was available only for the TCGA AML
data. We used 337 whole blood and 140 K562 Leukemia cell line sample data from the Genotype-Tissue
Expression (GTEx) project as controls.
4.5. Fluorescence in Situ Hybridization (FISH) and Image Capture
Metaphase chromosome and interphase nuclei from the patients analyzed here were obtained
from the archival material stored in methanol-acetic acid. Dual-color FISH experiments on metaphase
chromosomes and interphase nuclei were performed using a selection of probes mapping at different
sites in the long arm of chromosome 7 (see Table 2 for list of probes and corresponding chromosomal
location). In particular, for the mapping of HLXB9 on 7q36.3, we used the PAC RP5-1121A15
(GenBank accession No. AC006357.5) containing the gene. We also used commercially available probe
mixtures XL 7q22/7q36, containing the KMT2E and EZH2 genes, and XL del(7)(q22q31), containing the
KMT2E and MET genes (MetaSystems, Athlussein, Germany). Other probes included chromosome 7
paint directly labeled in green (Cambio, Cambridge, UK), BACs RP11-90N9 (GenBank accession No.
AZ518618.1), RP11-213E22 (GenBank accession No. AQ484445.1), RP11-73H23 (GenBank accession No.
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AQ266610.1). Additionally, we included probes previously used and described in [58]. These were:
Cosmid clones Cos5.3, Cos7d.2, Cos8a.2, Cos1107, Cos1120 and YAC clones HSC7E485, HSC7E124,
HSC7E86, HSC7E769, and the PAC clone 1065. Probes were labeled either directly with fluorochromes,
or indirectly with biotin or digoxigenin, using nick translation (Roche, Mannheim, Germany), and
detected according to standard methods previously described [21]. FISH experiments were carried out
as previously described [10,82]. Hybridization signals on metaphase chromosomes and interphase
nuclei were analyzed using an Olympus AX70 fluorescence microscope, and images were captured
using MacProbe v4.3 software (Applied Imaging, Newcastle, UK).
4.6. Radial Nuclear Positioning Analysis
Radial nuclear location (RNL) of HLXB9 and other relevant loci was based on two dimensional
(2D) analysis of FISH images of interphase nuclei as previously described [10,21]. Briefly, the RNL
of each hybridization signal was determined as the ratio of the nuclear radius. The numerical value
(namely the position of the hybridization signals along the nuclear radius) ranges between 0 and
1, where 0 indicates the cent and 1 the outer extreme of the nucleus. Depending on sample quality,
we aimed at scoring at least 200 nuclei per sample. The localization of large number of hybridization
signals relative to specific loci was determined according to well-established statistical methods that
take into consideration the median value of all signals +/− confidence interval (CI) [10]. According to
these methods, median values lower than 0.650 are indicative of loci positioned towards the nuclear
interior [10,28,32,38].
The statistical analysis and the corresponding graphs were carried out using Microsoft Excel and
StatView software (SAS Institute Inc., Cary, USA) [83]. Statistical significance was evaluated using the
Two-tailed t-test.
5. Conclusions
In this study, we address the radial nuclear repositioning of a gene in relation to the compositional
properties of chromosomal bands involved in a chromosomal deletion and its effect onits transcriptional
activation. We show here that the repositioning of HLXB9 in the nuclei of leukemia cells with del(7q)
depends on the location of the breakpoints on chromosome 7, which implies the disruption and
re-joining of different chromosomal bands. This type of repositioning may influence the nuclear
organization of the chromatin and the transcriptional activity of the repositioned genes. We show that
HLXB9 becomes activated when relocated to the inner part of the nucleus, consistent with previously
described observations [28,32,38]. We believe that our results will open new grounds for research in
the field of cancer genome organization, sheding some light into the mechanisms leading to gene
repositioning and gene regulation in tumor initiation and progression.
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